Company performance
Add to research
Current Price
as of May 20, 2025$53.45
P/E Ratio
14.18
Market Cap
$6.59B
Description
Add to research
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
Metrics
Add to research
Overview
- HQSan Diego, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerHALO
- Price$53.45+0.29%
Trading Information
- Market cap$6.59B
- Float98.90%
- Average Daily Volume (1m)3,211,846
- Average Daily Volume (3m)2,136,828
- EPS$3.86
Company
- Revenue$1.08B
- Rev growth (1yr)35.22%
- Net income$118.10M
- Gross margin75.02%
- EBITDA margin61.16%
- EBITDA$161.98M
- EV$8.84B
- EV/Revenue8.15
- P/E14.18
- P/S6.24
- P/B13.65
- Debt/Equity312.57
Documents
Add to research
SEC Filings
Earnings Calls
Factset Street Account
Wikipedia